Alterity Wins FDA Backing on Key Elements of ATH434 Phase 3 Plan

Alterity Therapeutics ( (AU:ATH) ) has issued an announcement.

Alterity Therapeutics has received positive written feedback from the U.S. Food and Drug Administration following a Type C Meeting on its planned Phase 3 development program for ATH434 in Multiple System Atrophy. The regulator supported the company’s plans for clinical pharmacology and non-clinical development components, marking a key regulatory milestone toward initiating a pivotal Phase 3 trial.

The company now plans to seek further agreement with the FDA on Chemistry, Manufacturing, and Controls, as well as the Phase 3 trial design, with an End-of-Phase 2 meeting targeted for mid-2026. The favorable interaction strengthens Alterity’s regulatory pathway for ATH434 and underscores its progress in advancing a potential disease-modifying treatment for a rare, rapidly progressive neurodegenerative condition.

The most recent analyst rating on (AU:ATH) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.

More about Alterity Therapeutics

Alterity Therapeutics is a clinical-stage biotechnology company developing disease-modifying therapies for neurodegenerative diseases, with a primary focus on Multiple System Atrophy (MSA) and related Parkinsonian disorders. Its lead candidate, ATH434, has shown clinically meaningful efficacy in a Phase 2 placebo-controlled trial and additional positive data in an open-label study in advanced MSA, supported by a broader discovery platform for novel neurological treatments.

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$87M

See more data about ATH stock on TipRanks’ Stock Analysis page.